Clinical trials: Epirubicin
Triple Negative Breast Cancer
Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy
This study will evaluate the efficacy and safety of antharcycline-based adjuvant chemotherapy compared with observation in triple negative breast cancer (TNBC) patients with residual invasive disease after platinum and taxanes…
- Trial name
- NCT04437160
- Testing
- Epirubicin or Pirarubicin, Cyclophosphamide
- Where
- China
- Volunteers
- 286 people
- Sponsor
- Chinese Academy of Medical Sciences
Pathological Response Rate
Assessment of the Efficacy of the Neoadjuvant Combination: "Chemotherapy-Targeted Therapy" in Breast Cancer.
The purpose of this study is to assess the pathological response rate in operable breast cancer patients treated by neoadjuvant combination: "FEC-Taxotere/Vectibix".
- Trial name
- TVA (NCT00933517)
- Testing
- vectibix, fluorouracile, Epirubicine
- Where
- 12 sites in France
- Volunteers
- 62 people
- Sponsor
- Centre Jean Perrin
Leiomyosarcoma
Temozolomide for Injection Combined With Epirubicin in First-line Treatment of Leiomyosarcoma
This study is a single-center, prospective, one-arm clinical study, which is planned to be carried out in Cancer Hospital of Chinese Academy of Medical Sciences.
- Trial name
- NCT05204524
- Testing
- Temozolomide for injection combined with epirubicin
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Chinese Academy of Medical Sciences
Breast Cancer, Neoadjuvant Therapy
Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy
Iparomlimab and Tuvonralimab Injection (QL1706) is a bifunctional combination antibody targeting both programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4).
- Conditions
- Breast Cancer, Neoadjuvant Therapy, Immune Checkpoint Inhibitors, QL1706
- Trial name
- NCT07372079
- Testing
- QL1706 combined with Chemotherapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Breast Cancer
Study of Alimta and Epirubicin Administered in Patients With Locally Advanced or Metastatic Breast Cancer
This is a non-randomized Phase 2 portion of a study testing ALIMTA and epirubicin in combination for locally advanced or metastatic breast cancer. Epirubicin is a well-established drug for the therapy of breast cancer.
- Trial name
- NCT00097383
- Testing
- ALIMTA plus Epirubicin
- Where
- 25 sites in Argentina, Belgium and 3 more
- Sponsor
- Eli Lilly and Company
Ovarian Cancer, Sarcoma
Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Ovarian Cancer, Sarcoma, Small Intestine Cancer
- Trial name
- NCT00025441
- Testing
- dactinomycin, filgrastim, carboplatin
- Where
- 22 sites in France, Ireland and 1 more
- Sponsor
- Societe Internationale d'Oncologie Pediatrique
TNBC - Triple-Negative Breast Cancer
Neoadjuvant Fluzoparib in Germline BRCA-mutated Three-negative Breast Cancer Breast Cancer
Although many PARP inhibitors did not improve pCR in neoadjuvant studies, it is not an unchallenged conclusion that TNBC does not benefit from use of PARP inhibitors in neoadjuvant therapy.This study is an open-label, two-cohort…
- Trial name
- NCT05834582
- Testing
- Fluzoparib+Paclitaxel, Epirubicin+Cyclophosphamide
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Breast Cancer
Epirubicin and Vinorelbine in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as epirubicin and vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00176488
- Testing
- epirubicin, vinorelbine
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Breast Neoplasms, Adjuvant
Study of Suitable Schedule of Docetaxel,Anthracycline and Cyclophosphamide in Adjuvant Therapy of Beast Cancer
Anthracycline based regimens followed by a taxane (CALGB-9344 trial and NSABP-B28) or reversed (MD Anderson Adjuvant Trial) has already accepted as adjuvant therapy for node positive breast cancer.
- Conditions
- Breast Neoplasms, Adjuvant, Chemotherapy
- Trial name
- NCT00525642
- Testing
- Docetaxel, Doxorubicin or Epirubicin, Cyclophosphamide
- Where
- 5 sites in China
- Volunteers
- 603 people
- Sponsor
- Fudan University
Breast Neoplasms, Neoadjuvant Therapy
Neoadjuvant ECS Versus ECF in Local Advanced Breast Cancer
S-1 is a newly developed novel oral dihydrouracil dehydrogenase inhibiting fluoro-pyrimidine drug consisting of i M tegafur (FT), 0.4 M 5-chloro-2, 4-dihydroxypyrimidine (gimeracil), and 1 M potassium oxonate (oteracil), with…
- Trial name
- NCT01849380
- Testing
- S-1, 5-FU
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Shandong University
Breast Neoplasm
The Study of Trilaciclib Combined With Chemotherapy On The Neoadjuvant Therapy of TNBC
To evaluate the efficacy and safety of trilaciclib combined with standard treatment project as a neoadjuvant treatment for triple negative breast cancer
- Trial name
- NCT05862610
- Testing
- Trilaciclib plus chemotherapy, Chemotherapy
- Volunteers
- 150 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Gallbladder Neoplasms
New Chemotherapy Regimen in the Treatment of Advanced Gallbladder Carcinoma
Objective Primary: Determine the objective response rate in patients with advanced gallbladder treated with new Chemotherapy regimen Secondary: Determine time to progression-free survival and overall survival of patients treated…
- Trial name
- NCT01053390
- Testing
- Somatostatin, epirubicin, cisplatin, LV（Leucovorin）、 5-FU（5-Fluorouracil）
- Where
- China
- Volunteers
- 216 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Breast Cancer
Randomized Phase II Study of Epirubicin vs Caelyx in Pretreated Metastatic Breast Cancer
DOXORUBICIN is recognized as one of the most active drugs for breast cancer, but its clinical utility is limited because of a cumulative dose-dependent cardiac myopathy that can lead to potentially fatal congestive heart failure.
- Trial name
- NCT00431795
- Testing
- Pegylated liposomal doxorubicin (Caelyx), Epirubicin
- Where
- 10 sites in Greece
- Volunteers
- 100 people
- Sponsor
- Hellenic Oncology Research Group
Breast Cancer
Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer
The efficacy of adjuvant chemotherapy is limited in patients with a high risk of recurrence. Also, for axillary positive node patients, optimum chemotherapy regimens are still under discussion.
- Trial name
- NCT00129922
- Testing
- paclitaxel, Fluorouracil, Epirubicin
- Where
- 64 sites in Spain
- Volunteers
- 1,289 people
- Sponsor
- Spanish Breast Cancer Research Group
Diffuse Large B-cell Lymphoma
R±CEOP90 Versus R±CEOP75 in Newly Diagnosed Young Patients With Medium/High-risk DLBCL
This clinical trial is designed to compare the efficacy and safety of R±CEOP90 containing high-dose epirubicin and R±CEOP75 containing standard epirubicin in newly diagnosed young patients with medium/high-risk diffuse large…
- Trial name
- NCT03151044
- Testing
- High-dose Epirubicin Combined with CVP ± Rituximab, Standard-dose Epirubicin Combined with CVP ± Rituximab
- Where
- 9 sites in China
- Volunteers
- 408 people
- Sponsor
- FENG Ji-feng
Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow patients to tolerate higher doses…
- Conditions
- Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Ovarian Cancer, Testicular Germ Cell Tumor
- Trial name
- NCT00003852
- Testing
- filgrastim, carboplatin, cyclophosphamide
- Where
- 18 sites in France
- Volunteers
- 45 people
- Sponsor
- UNICANCER
Neoplasms, Breast
A Phase I, Open-label, Study of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tumors
This is an open-label, four-arm, Phase I, dose escalation study to evaluate the safety and tolerability and to determine the optimal tolerated regimen (OTR) of pazopanib in combination with epirubicin or doxorubicin in patients…
- Trial name
- NCT00722293
- Testing
- Doxorubicin, Pazopanib (GW786034), Epirubicin
- Where
- 4 sites in Italy, Switzerland
- Volunteers
- 111 people
- Sponsor
- GlaxoSmithKline
GIST, Malignant, Liver Metastases
Comparison of Clinical Efficacy of Liver Resection, RFA, TACE, and Drug Therapy in Patients with GIST LM
The goal of this observational study is to evaluate the overall survival benefits of local treatment combined with imatinib(IM) and IM alone in patients suffering from GIST liver metastases.
- Trial name
- NCT06038552
- Testing
- imatinib (IM), hepatic resection (HR), radiofrequency ablation (RFA)
- Where
- China
- Volunteers
- 238 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Breast Cancer
Early Cardiac Toxicity of Adjuvant CT in Elderly BC.
The primary objective is to evaluate the difference in cardiac strain rate evolution in elderly early BC patients treated with (neo) adjuvant anthracycline-based chemotherapy compared with a non-anthracycline regimen…
- Trial name
- NCT01301040
- Testing
- epirubicin, cyclophosphamide, docetaxel
- Where
- Belgium
- Volunteers
- 2 people
- Sponsor
- Jules Bordet Institute
Breast Cancer
Late Cardiac Evaluation of the Three Arm Belgian Trial Involving Node-positive Early Breast Cancer Patients
Late Cardiac Evaluation of the Three Arm Belgian Trial A phase III randomized trial involving node-positive early breast cancer patients with a long median follow-up (~ 15 years) OBJECTIFS Primary: To compare the incidence of…
- Trial name
- NCT01554943
- Testing
- cardiac MRI
- Where
- Belgium
- Volunteers
- 73 people
- Sponsor
- Jules Bordet Institute